Physician profile
Sarah Spriet
NPI 1841584893
$9,100.36
in general payments reported to CMS, 2019-2025
8 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 75% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.96 · 2022: $168 · 2023: $4,380 · 2024: $2,000 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $4,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $4,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $379.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,584.05 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $256.72 | 2022-2023 | Fasenra |
| Glaxosmithkline, LLC. | $94.90 | 2022-2023 | Nucala |
| Csl Behring | $91.46 | 2019-2023 | Hizentra |
| Pharming Healthcare, INC. | $24.58 | 2023 | Ruconest |
| Aimmune Therapeutics, INC. | $18.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.02 | 2022 | |
| Greer Laboratories, INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Spriet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.